open access

Vol 7, No 5 (2011)
Review paper
Published online: 2011-12-09
Get Citation

Molecularly-targeted therapy of gastric cancer

Krzysztof G. Jeziorski
Onkol. Prak. Klin 2011;7(5):258-263.

open access

Vol 7, No 5 (2011)
REVIEW ARTICLES
Published online: 2011-12-09

Abstract

Gastric cancer is a heterogeneous malignancy with expression of many molecular factors. Trastuzumab is the first biologic drug (targeted therapy) that has shown benefits in terms of increased median overall survival. Trastuzumab in combination with chemotherapy is indicated in metastatic gastric or gastrooesophageal junction cancer in patients with no prior exposure to systemic anticancer therapy for disseminated disease and with HER2 protein overexpression (score of IHC 3+) regardless of HER2 gene copy number and with expression of 2+ combined with HER2 gene amplification, although clinical benefits in this group are much less evident.
Onkol. Prak. Klin. 2011; 7, 5: 258–263

Abstract

Gastric cancer is a heterogeneous malignancy with expression of many molecular factors. Trastuzumab is the first biologic drug (targeted therapy) that has shown benefits in terms of increased median overall survival. Trastuzumab in combination with chemotherapy is indicated in metastatic gastric or gastrooesophageal junction cancer in patients with no prior exposure to systemic anticancer therapy for disseminated disease and with HER2 protein overexpression (score of IHC 3+) regardless of HER2 gene copy number and with expression of 2+ combined with HER2 gene amplification, although clinical benefits in this group are much less evident.
Onkol. Prak. Klin. 2011; 7, 5: 258–263
Get Citation

Keywords

gastric cancer; targeted therapy; trastuzumab

About this article
Title

Molecularly-targeted therapy of gastric cancer

Journal

Oncology in Clinical Practice

Issue

Vol 7, No 5 (2011)

Article type

Review paper

Pages

258-263

Published online

2011-12-09

Bibliographic record

Onkol. Prak. Klin 2011;7(5):258-263.

Keywords

gastric cancer
targeted therapy
trastuzumab

Authors

Krzysztof G. Jeziorski

Important: This website uses cookies. More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

Wydawcą serwisu jest  "Via Medica sp. z o.o." sp.k., ul. Świętokrzyska 73, 80–180 Gdańsk

tel.:+48 58 320 94 94, faks:+48 58 320 94 60, e-mail:  viamedica@viamedica.pl